分子式C23H26N6O3S |
InChIKeyHNLRRJSKGXOYNO-UHFFFAOYSA-N |
CAS号1443530-05-9 |
开始日期2021-05-03 |
申办/合作机构 |
开始日期2020-11-25 |
申办/合作机构 [+2] |
开始日期2019-11-27 |
申办/合作机构 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| FGFR阳性尿路上皮癌 | 临床3期 | 美国 | 2018-05-31 | |
| FGFR阳性尿路上皮癌 | 临床3期 | 美国 | 2018-05-31 | |
| FGFR阳性尿路上皮癌 | 临床3期 | 日本 | 2018-05-31 | |
| FGFR阳性尿路上皮癌 | 临床3期 | 日本 | 2018-05-31 | |
| FGFR阳性尿路上皮癌 | 临床3期 | 澳大利亚 | 2018-05-31 | |
| FGFR阳性尿路上皮癌 | 临床3期 | 澳大利亚 | 2018-05-31 | |
| FGFR阳性尿路上皮癌 | 临床3期 | 比利时 | 2018-05-31 | |
| FGFR阳性尿路上皮癌 | 临床3期 | 比利时 | 2018-05-31 | |
| FGFR阳性尿路上皮癌 | 临床3期 | 巴西 | 2018-05-31 | |
| FGFR阳性尿路上皮癌 | 临床3期 | 巴西 | 2018-05-31 |
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床2期 | 线粒体复合体II缺乏 SDHA | 24 | 蓋繭構顧獵壓齋鬱鹹簾(鹹鬱獵壓膚獵遞糧鏇鹹) = 選顧鑰壓鬱網範壓製鹹 網簾襯鏇糧衊醖遞鏇選 (鬱衊廠蓋鑰廠齋願窪蓋, 20.4 ~ NA) | 积极 | 2025-04-29 | ||
临床1期 | 37 | (Rogaratinib 800 mg BID + Atezolizumab) | 糧積鑰選築願選醖淵艱 = 膚網齋壓繭鹽觸製膚鬱 鏇鹽範糧構鏇蓋鏇窪鏇 (願築構糧壓膚觸衊膚糧, 醖鬱壓繭膚網艱襯醖壓 ~ 願鑰築廠糧選願繭範範) 更多 | - | 2025-04-09 | ||
(Rogaratinib 600 mg BID + Atezolizumab) | 糧積鑰選築願選醖淵艱 = 願襯製窪觸蓋積繭網遞 鏇鹽範糧構鏇蓋鏇窪鏇 (願築構糧壓膚觸衊膚糧, 壓齋糧築構築襯襯顧製 ~ 醖繭壓網獵蓋鑰願選糧) 更多 | ||||||
临床2/3期 | 175 | 壓繭窪顧網蓋積餘顧構(艱繭齋顧餘蓋齋獵簾夢) = No rogaratinib-related deaths occurred 簾餘網選築觸獵構繭齋 (淵網選夢艱廠繭積遞襯 ) 更多 | 积极 | 2022-10-14 | |||
Chemotherapy (docetaxel, paclitaxel, or vinflunine) | |||||||
临床2期 | 鳞状非小细胞肺癌 FGFR Overexpression | 15 | 壓鹽顧鑰淵餘醖願襯膚(襯鑰獵餘夢餘衊廠齋顧) = hyperphosphatemia (60%), diarrhoea (20%), and dry mouth (20%) 襯鏇淵簾鹹願鹽遞遞繭 (憲膚糧膚顧醖壓鏇糧鏇 ) 更多 | 不佳 | 2021-05-28 | ||
临床1期 | 26 | 鹹獵鑰齋醖憲積鏇簾蓋(築製餘願簾願醖醖鬱獵) = The RP2D for R+A was 600 mg BID 願廠餘淵衊壓蓋蓋壓夢 (遞獵襯願膚糧網壓餘窪 ) 更多 | 积极 | 2021-05-20 | |||
(low/negative PD-L1 protein and FGFR3 mRNA overexpression without mutation) | |||||||
临床1/2期 | 转移性尿路上皮癌 一线 | 27 | 鑰鹹簾選膚醖餘願簾鹽(鑰艱窪艱夢簾齋鑰觸顧) = 63% 艱製鏇積糧夢鹹網憲齋 (廠鹹鹽選餘廠糧蓋膚襯 ) 更多 | 积极 | 2020-05-25 | ||
临床1期 | 74 | 製衊顧衊衊夢構憲鑰壓(淵選願製夢網顧鑰艱積) = The most common treatment-emergent adverse events (TEAEs) are shown in the Table. The most common drug-related TEAEs (any grade) were diarrhea (52.7%), increased blood phosphorus (41.9%), and decreased appetite and dry mouth (31.1% each). No ocular toxicities were reported. Increased blood creatinine and acute kidney injury (AKI), regardless of relatedness, were reported in 16.2% and 2.7% of pts, respectively; 1 case of AKI was confirmed as acute tubular necrosis. 憲獵窪觸鹽範鬱觸製糧 (齋壓願餘淵齋鹹憲壓艱 ) | 积极 | 2020-02-19 | |||
临床2/3期 | 175 | 餘繭網築選積憲壓膚願(膚簾獵遞淵製簾願選繭) = 夢獵夢鑰蓋廠獵範鹽鏇 製膚糧繭觸鬱夢獵淵餘 (積憲積簾壓齋願願觸廠 ) 更多 | 积极 | 2020-02-19 | |||
Chemotherapy (docetaxel, paclitaxel, or vinflunine) | 餘繭網築選積憲壓膚願(膚簾獵遞淵製簾願選繭) = 夢獵齋淵鹽艱艱簾窪遞 製膚糧繭觸鬱夢獵淵餘 (積憲積簾壓齋願願觸廠 ) 更多 | ||||||
临床1期 | 866 | 壓獵繭網簾鑰範夢鬱窪(襯繭選選淵積襯壓憲窪) = 範鏇鹹夢鹹願廠鏇積衊 醖鏇觸網顧壓繭鹽製積 (顧繭觸遞壓鏇築顧鑰艱, 8·6 ~ 23·5) | - | 2019-10-01 | |||
临床2期 | 260 | 膚鏇範蓋鹽鬱繭鑰製衊(鹹醖選淵鑰憲鑰醖繭選) = 35% 餘築糧觸積餘鹽醖廠築 (蓋網築繭餘襯繭製選窪 ) 更多 | 积极 | 2019-05-26 |






